ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2191

Optimizing Inpatient Kawasaki Disease Care

Audrea Chen1, Beth Gamulka2, Macarena Palomer3 and Rae Yeung4, 1The Hospital for Sick Children, Burnaby, BC, Canada, 2The Hospital for Sick Children, Toronto, 3The Hospital for Sick Children, Toronto, Canada, 4The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

Meeting: ACR Convergence 2024

Keywords: education, patient, Pediatric rheumatology, quality of care, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Pediatric Rheumatology – Clinical Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Kawasaki Disease (KD), an acute pediatric vasculitis, requires inpatient management to prevent coronary artery disease. The Hospital for Sick Children (SickKids) sees about 100 cases of KD annually. Hospitalization and lack of reliable educational resources negatively impact the patient and family experience. By eliminating inefficiencies, reducing length of stay (LOS) and improving patient education, we aim to optimize patient experience and conserve healthcare resources. The objective is to optimize inpatient care for uncomplicated KD by reducing LOS by 33% at SickKids by April 2024.

Methods: This is a quality improvement time series using the Model for Improvement Framework. The project includes patients diagnosed and treated at SickKids. Stakeholders include Paediatric Medicine, Rheumatology, KD clinic, Transfusion Medicine and parent representatives.

Chart review of patients with KD in 2023 demonstrated a baseline average LOS of 56 hours. Root cause analysis included focus groups, interviews, a process map outlining the KD admission (Fig. 1) and a Pareto diagram. A new clinical KD pathway was created incorporating 4 key change ideas: simplification of the echocardiography process, reduction of unnecessary blood tests, implementation of a discharge checklist and improvement of patient educational resources. Change ideas were linked to primary and secondary drivers of change through a driver diagram (Fig. 2).

The outcome measure is LOS for uncomplicated KD, which excludes those with refractory disease, concurrent complicated infection, shock and coronary artery dilation/aneursym on the hospital echocardiogram. Process and balancing measures included all patients admitted for KD. Process measures examined the fidelity of the change ideas. Balancing measures included rate of re-presentation to emergency care, untreated fever and patient satisfaction. Cost savings were estimated by calculating reductions in hours of admission as well as unnecessary bloodwork.

Results: Fifteen patients were admitted with KD since implementation of change ideas in December 2023, 8 had uncomplicated KD. The average LOS for uncomplicated KD was 41 hours, which is about a 25% reduction from baseline (Fig. 3). Process measures among 15 patients showed good uptake in change ideas. There was no increase in emergency services use among discharged patients, nor incidences of untreated fever. Six patients responded to the satisfaction survey with 100% feeling satisfied with the education received in hospital. There was an estimated $8936.75 in cost savings over 15 admissions.

Conclusion: The LOS for uncomplicated KD was reduced by 25% through strong uptake of the new simplified clinical KD pathway which did not negatively impact patient safety nor satisfaction. The project was strengthened by strong stakeholder relationships, patient/caregiver involvement and the use of automation and forced functions.

Supporting image 1

Process map swimlane diagram demonstrating the patient flow from presentation in the Emergency Department to discharge. Estimated times in red are averaged from 5 patients meeting inclusion criteria in chart review. Each step was annotated for value to the patient based on stakeholder discussion. NVN denotes a step that is necessary to complete the process but does not provide direct value to the patient. Flow efficiency was calculated by dividing the total number of steps by the number of value-added steps. MOH: Ministry of Health. IVIG: IV immunoglobulin.

Supporting image 2

Driver Diagram developed based on root cause analysis for drivers of change and change ideas. Ultimately 4 change ideas were introduced in December 2023. Post-IVIG bloodwork was deemed unnecessary and thus the second change idea was altered to remove the bloodwork completely from the order set. The family of measures is listed on the right, with the numbered process measures mapping to their respective change ideas. DAT = direct antiglobulin test. IVIG = IV immunoglobulin. AVS: After Visit Summary.

Supporting image 3

Statistical Process Control XmR Chart tracking length of stay (LOS) for Kawasaki Disease (KD) patients meeting inclusion criteria from January 2023 – April 2024. The intervention began in mid-December 2023. Target line is set at 36 hours for a 30% reduction in LOS. The median baseline LOS is 52 hours. No significant variation noted in the process thus far.


Disclosures: A. Chen: None; B. Gamulka: None; M. Palomer: None; R. Yeung: None.

To cite this abstract in AMA style:

Chen A, Gamulka B, Palomer M, Yeung R. Optimizing Inpatient Kawasaki Disease Care [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/optimizing-inpatient-kawasaki-disease-care/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/optimizing-inpatient-kawasaki-disease-care/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology